NYSEAMERICAN:HEB - Hemispherx Biopharma, Inc.
$4.00
 $0.05
+1.27%
11:55AM EDT
2019-07-22
Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company. The Company is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. The Company's segment is engaged in research and development activities related to Ampligen and other drugs under development, and sales and marketing of Alferon. The Company's products include Alferon N Injection and Ampligen. Alferon N Injection is approved for the use in intralesional treatment of refractory or recurring external genital warts in patients of over 18 years of age. Ampligen is a drug undergoing clinical development for the treatment of Chronic Fatigue Syndrome (CFS). Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) is a low-dose, oral liquid formulation of natural alpha interferon. Alferon LDO is a liquid natural interferon for oral administration. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  HEB     avg for
industry  
  avg for
sector  
42 stocks weight:  -1000. 00 M 217. 37   399. 45  
42 stocks rank:  4. 59 K 1. 27 K 716. 99  
# analyst opinions:  2. 00   13. 21   13. 71  
mean recommendation:  2. 00   2. 10   2. 04  

quick ratio:  2. 39   5. 49   1. 88  
current ratio:  2. 81   5. 87   2. 36  

target price low:  2. 64   83. 44   114. 90  
target price avg:  5. 47   106. 20   137. 90  
target price high:  8. 00   132. 30   158. 97  
1-yr high:  13. 64   111. 86   142. 57  
last close:  3. 95   86. 79   125. 44  
50-day avg:  4. 93   86. 68   122. 63  
200-day avg:  7. 76   89. 22   121. 38  
1-yr low:  3. 84   69. 78   100. 51  
volume:  68. 54 K 2. 62 M 3. 43 M
50-day avg volume:  175. 49 K 3. 20 M 4. 16 M
200-day avg volume:  70. 87 K 2. 99 M 4. 75 M

1-day return:  -2. 47 % -1. 30 % -0. 99 %
this week return:  -4. 13 % 0. 45 % -0. 20 %
12-wk return:  -40. 15 % 0. 94 % 4. 84 %
52-wk return:  -70. 16 % -1. 30 % 10. 55 %

enterprise value (EV):  11. 94 M 45. 10 B 122. 38 B
market cap:  8. 71 M 38. 96 B 108. 40 B
EBITDA:  -10. 97 M 4. 20 B 8. 19 B
enterprise multiple (EV/EBITDA):  -1. 09   5. 38   11. 93  
enterprise/revenue (EV/R):  38. 40   57. 92   10. 21  
total revenue:  311. 00 K 9. 91 B 39. 98 B
total debt:  6. 29 M 10. 90 B 17. 48 B
debt/equity:  160. 05   57. 18   120. 05  
net income (common):  -10. 47 M 2. 07 B 4. 05 B

shares outstanding:  251. 49 K 538. 09 M 1. 24 B
shares:  1. 84 M 548. 00 M 1. 22 B
shares short:  144. 55 K 10. 98 M 11. 87 M
shares short prior month:  72. 91 K 9. 32 M 12. 05 M
short ratio:  0. 56   5. 60   3. 34  
short % of float:  9. 52 % 6. 48 % 2. 64 %
total cash/share:  2. 48   10. 98   9. 19  
total cash:  4. 88 M 5. 93 B 6. 10 B
free cash flow:  -6. 38 M 2. 92 B 4. 55 B
operating cash flow:  -9. 55 M 3. 80 B 5. 78 B

book value:  0. 99   13. 35   27. 45  
price/book:  4. 00   4. 60   8. 78  
gross profits:  -517. 00 K 7. 44 B 36. 13 B
operating margins:  -3797. 75 % -308. 40 % -28. 55 %
EBITDA margins:  0. 00 % 13. 17 % 23. 38 %
profit margins:  0. 00 % 10. 44 % 14. 18 %
gross margins:  -191. 64 % 35. 80 % 55. 40 %

1-yr max volatility:  27. 83 % --- ---
1-yr mean volatility:  3. 88 % 1. 66 % 1. 03 %

1-yr EPS:  -9. 63   2. 10   4. 23  
forward EPS:  -4. 46   3. 45   7. 10  
P/E:  -0. 41   1. 90   32. 10  
forward P/E:  -0. 91   6. 46   15. 47  
PE/G:  0. 01   0. 70   -0. 54  
growth:  -67. 04 % 265. 63 % 79. 11 %
earnings high:  -1. 64   0. 89   1. 68  
earnings avg:  -1. 70   0. 70   1. 57  
earnings low:  -1. 76   0. 46   1. 46  
revenue high:  70. 00 K 2. 57 B 11. 07 B
revenue avg:  60. 00 K 2. 51 B 10. 91 B
revenue low:  60. 00 K 2. 45 B 10. 73 B
return on assets:  -45. 81 % -2. 34 % 5. 28 %
return on equity:  -148. 17 % -90. 08 % 133. 53 %
revenue/share:  0. 29   12. 72   60. 04  

beta (1yr vs S&P500):  0. 46   1. 27   0. 91  
sharpe (1yr):  -0. 79   0. 16   0. 77  

held % insiders:  12. 78 % 6. 06 % 3. 29 %
held % institutions:  6. 09 % 78. 22 % 69. 37 %

Research more with google or yahoo!
the data below are updated and re-published at 8pm EDT after each trading day

2019-07-21 : HEB
.    101.548 =       101.548 :: --> INITIAL WEIGHT <--
.    - 9.626 =        91.922 :: earnings per-share addition
.                               --> FUNDAMENTALS <--
.    x 1.951 =       179.374 :: P/E factor
.    x 2.209 =       396.229 :: PE/G factor
.    x 1.357 =       537.486 :: beta factor
.    x 0.925 =       497.118 :: sharpe factor
.    x 2.478 =      1231.867 :: current ratio factor
.    x 1.312 =      1616.039 :: quick ratio factor
.    x 1.745 =      2819.243 :: short ratio factor
.    x 1.663 =      4688.073 :: EV/R factor
.    x 1.049 =       4916.14 :: price-to-book factor
.    x 0.655 =      3218.039 :: debt-to-revenue factor
.    x 1.341 =      4316.218 :: debt-to-equity factor
.                               --> PERFORMANCE <--
.    x 2.121 =      9153.806 :: sector+industry 1-year gains factor
.    x 1.009 =      9240.109 :: industry 12-weeks return factor
.    x 1.308 =     12085.033 :: industry 2-weeks return factor
.    / 2.169 =      5570.568 :: overall "drift" factor
.    x 0.567 =      3157.964 :: largest single-day jump factor
.    x 0.076 =       238.695 :: low price factor
.    x 2.262 =        539.91 :: notable returns + performance factor
.                               --> PROJECTIONS <--
.    x 0.621 =       335.453 :: forward EPS factor
.    x 0.862 =       289.292 :: forward P/E factor
.    x 1.185 =       342.728 :: industry recommendation factor
.    x 2.098 =       719.099 :: company recommendation factor
.    x 1.003 =       721.087 :: factor historical industry gain for week 29
.    x 0.912 =       657.711 :: target low factor
.    x 1.207 =       793.938 :: target mean factor
.    x 1.043 =       827.703 :: target high factor
.   x 10.214 =      8454.063 :: spline projection factor
.                               --> FINAL ADJUSTMENTS <--
.  quad root =         9.589 :: reduced for readability
.   + 13.784 =        23.373 :: add/subtract for investor sentiment
. -999999999.999 zero/no returns for 10 days out of the past 42x trading days
.                               --> FINAL WEIGHT <--
.                  -999999999.999 :: FINAL WEIGHT for NYSEAMERICAN:HEB


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org